Suppression of AKT potentiates synergistic cytotoxicity of apigenin with TRAIL in anaplastic thyroid carcinoma cells

Anticancer Research

Volumn 35, Issue 12, 2015, Pages 6529-6538

  Kim, Si Hyoung ^a   Kang, Jun Goo ^a   Kim, Chul Sik ^a   Ihm, Sung Hee ^a   Choi, Moon Gi ^a   Yoo, Hyung Joon ^a   Lee, Seong Jin ^a  

^a Hallym University   (South Korea)

Author keywords

AKT; Anaplastic thyroid carcinoma; Apigenin; Bcl2; TRAIL

Indexed keywords

APIGENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; THYROID CARCINOMA; WESTERN BLOTTING; CELL CULTURE TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; TUMOR CELL LINE;

APIGENIN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84949477511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smith N and Nucera C: Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab 100: 35-42, 2015.
2. Shukla S and Gupta S: Apigenin: a promising molecule for cancer prevention. Pharm Res 27: 962-978, 2010.
3. Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI and Gupta S: Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 67: 6925-6935, 2007.
4. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Apigenin induces c-Myc-mediated apoptosis in FRO anaplastic thyroid carcinoma cells. Mol Cell Endocrinol 369: 130-139, 2013.
5. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E. J Endocrinol Invest 36: 1099-1104, 2013.
6. Cha HY, Lee BS, Kang S, Shin YS, Chang JW, Sung ES, Kim YS, Choi JW, Kim JH and Kim CH: Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death. Ann Surg Oncol 20: S716-724, 2014.
7. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75, 2003.
8. Sung ES, Park KJ, Choi HJ, Kim CH and Kim YS: The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res 318: 1564-1576, 2012.
9. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G, Gulisano M and De Maria R: Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 92: 1938-1942, 2007.
10. Park JW, Wong MG, Lobo M, Hyun WC, Duh QY and Clark OH: Modulation of tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. Thyroid 13: 1103-1110, 2003.
11. Horinaka M, Yoshida T, Shiraishi T, Nakata S, Wakada M and Sakai T: The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 5: 945-951, 2006.
12. Kim EY and Kim AK: Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis. Biomol Ther 20: 62-67, 2012.
13. Kim EY, Yu JS, Yang M and Kim AK: Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERKdependent up-regulation of TRAIL receptor DR5. Mol Cells 35: 32-40, 2013.
14. Oishi M, Iizumi Y, Taniguchi T, Goi W, Miki T and Sakai T: Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS One 8: e55922, 2013.
15. Szliszka E, Czuba ZP, Jernas K and Krol W: Dietary flavonoids sensitize HeLa cells to tumor necrosis factor-related apoptosisinducing ligand (TRAIL). Int J Mol Sci 9: 56-64, 2008.
16. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
17. Xing M: Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20: 697-706, 2010.
18. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: CCAAT/enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells. Horm Metab Res 45: 9-14, 2013.
19. Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm Metab Res 45: 408-414, 2013.
20. Schroder-van der Elst JP, van der Heide D, Romijn JA and Smit JW: Differential effects of natural flavonoids on growth and iodide content in a human Na+/I-symporter-transfected follicular thyroid carcinoma cell line. Eur J Endocrinol 150: 557-564, 2004.
21. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L and Fusco A: Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasomedependent inhibition of TRAIL degradation. Oncogene 29: 105-116, 2010.
22. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
23. Cory S and Adams JM: Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8: 5-6, 2005.
24. Sun Q, Jiang S, Yang K, Zheng J, Zhang L and Xu W: Apigenin enhances the cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand in human rheumatoid arthritis fibroblast-like synoviocytes. Mol Biol Rep 39: 5529-5535, 2012.